Navigation Links
Smallpox vaccine alternative identified
Date:1/7/2008

Irvine, Calif., Jan. 7, 2008 University of California, Irvine infectious disease researchers have shown the effectiveness of a potential alternative to the existing smallpox vaccine that can replace the current biodefense stockpile for this lethal virus.

Philip Felgner and Huw Davies with the Department of Medicine found that the modified vaccinia virus Ankara (MVA) produced the same antiviral response in human and animal studies as the current smallpox vaccine, Dryvax. The study is part of a national effort to develop a replacement for the Dryvax vaccine, which causes serious complications in some people. The results are published in the Journal of Virology.

Studies have shown MVA to be a much safer vaccine product that takes advantage of modern technology, Felgner said. We are pleased that our advanced analytical methods may help to bring an effective and safer vaccine to the public.

Smallpox was declared eradicated worldwide in 1980; the last naturally occurring case in the world was in Somalia in 1977. Routine vaccination against smallpox in the U.S. stopped in 1972, and Dryvax production was halted in 1982.

Both Dryvax and MVA are strains of vaccinia virus, which is related to the smallpox virus. The antibodies created by vaccinia virus infection protect a person against a lethal smallpox infection, making it suitable for use as a vaccine. Unlike smallpox virus, vaccinia creates a very mild infection and is completely safe for healthy individuals.

Although Dryvax was effective during the eradication campaign in the 1960s and 70s, its manufacturing methods are outdated by todays standards, and it is also associated with significant risk of adverse reactions for immune-compromised individuals.

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, identified MVA as a possible candidate to replace Dryvax. MVA was first developed in the 1970s and has been administered to animal species and humans with little or no adverse side effects.

In the study, Felgner and Davies applied blood serum samples taken from both humans and animals given the MVA or Dryvax vaccines to microarray chips containing more than 200 vaccinia virus proteins, on which they simultaneously studied how the serum antibodies responded to all the vaccinia proteins.

The researchers found that these antibody responses were similar in both the animal and human subjects regardless whether they were given MVA or Dryvax, suggesting that MVA contains antiviral properties similar to those in Dryvax.

This similarity is vital, Davies says, because if a vaccine initiates an immune response in humans that matches the one in animals that are protected against lethal pox viruses, then public health officials will have more confidence that the vaccine will be effective in humans.

This is particularly important for vaccines against lethal infections like smallpox, where human clinical trials cannot be done, he added.


'/>"/>

Contact: Tom Vasich
tmvasich@uci.edu
949-824-6455
University of California - Irvine
Source:Eurekalert

Related medicine news :

1. Bavarian Nordic Reports Positive Data from First EUA Enabling Study with IMVAMUNE(R) Smallpox Vaccine Candidate
2. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
3. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
4. Vaccine Stops Alzheimers Brain Tangles
5. Human Papilloma Virus vaccines may decrease chances of oral cancer
6. U.S. Teens Fall Short on Vaccine Coverage
7. Nasal Anthrax Vaccine Proves Effective in Animal Study
8. Hot ice, measuring depression, perfect invisibility and flu vaccine incentives
9. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
10. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
11. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2017)... (PRWEB) , ... May 28, 2017 , ... Starting in ... with Nerve-Express, the latest Heart Rate Variability (HRV) diagnostic test. , Nerve-Express, originally designed ... and R-R interval, indicating the state of a patient’s autonomic nervous system (ANS). ...
(Date:5/27/2017)... (PRWEB) , ... May 26, 2017 , ... A May ... who visit a doctor for colds or respiratory issues that are not responsive to ... time pressure on doctors may be largely responsible for the problem both in Canada ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Mediaplanet is ... Wound Care" campaign in USA Today, which will educate readers on how to take ... the campaign, a large focus is placed on melanoma. Dancing with the Stars professional, ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... the CareFusion NOX-T3 portable sleep monitor with its Somnoware Sleep Device Interface (SDI). ... interface for diagnostic device operations. With this platform, initializing devices and importing studies ...
(Date:5/26/2017)... ... 26, 2017 , ... After raising nearly $30,000 on Kickstarter , about ... available at a discounted crowdfunding price on Indiegogo . , “Along with creating ... wanted to bring a fidget toy to the market that was made of superior ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral ... Intellectual Property Office has granted Oramed a patent ... Exenatide". The patent covers Oramed,s invention of an ... is an incretin hormone that stimulates the secretion ...
(Date:5/6/2017)... Provista , a proven leader in the supply chain industry ... Jim Cunniff as the company,s new president and CEO. ... Provista, including most recently serving as the president and CEO ... He assumed his new role with Provista on May 1, ... says Jody Hatcher , president, Sourcing and Collaboration Services ...
(Date:5/4/2017)... MEMPHIS, Tenn. , May 4, 2017 /PRNewswire/ ... of Infection Control, Ultraviolet-C light as ... demonstrated Tru-D SmartUVC,s ability to reduce bioburden on ... influenced bioburden reduction on high-touch, complex medical equipment ... in surgical infections. "This study further ...
Breaking Medicine Technology: